Passage Bio Business Model Canvas

CROs and clinical trial networks manage multi-center trials, logistics, and data integrity for Passage Bio, coordinating complex site operations and regulatory compliance across regions. Rare disease networks accelerate patient identification and enrollment in a space of 7,000+ rare diseases affecting ~300 million people worldwide, improving recruitment velocity. Centralized imaging, PK/PD, and biomarker labs standardize endpoints and data harmonization. These partnerships compress timelines and enhance trial quality.

Collaborations with academia, CDMOs, CROs and patient groups accelerate CNS gene therapy, sharing up to 40% of preclinical costs and leveraging >1,000 engineered capsids (2024). Rare-disease networks (7,000+ groups) and registries cover ~300 million affected worldwide, speeding recruitment and regulatory evidence generation.

Process development improves AAV yield, purity and batch-to-batch consistency to meet clinical and commercial demands, reducing downstream costs and time to release. Robust release assays validate identity, potency and safety, enabling confident lot release for trials. Comparability protocols de-risk manufacturing changes across scales while comprehensive CMC documentation underpins regulatory approvals and lifecycle management.

Designing CNS‑targeted AAV capsids/constructs with promoter tuning and iterative in vitro/in vivo screening drives potency and safety; by 2024 two FDA AAV approvals validated clinical translation. Rigorous GLP preclinical packages and PK/PD modeling inform IND and first‑in‑human dosing. CMC scale‑up and release assays secure clinical supply. Adaptive trials, orphan/RMAT pathways and HE models support pricing and payer arrangements.

Access to dedicated GMP suites, validated processes, and QC assays underpins supply reliability for Passage Bio, ensuring consistent batch-to-batch quality. In-house capacity plus partnered manufacturing supports clinical programs and early commercial launches. Robust release testing and stability programs maintain regulatory compliance. Tight supply-chain controls reduce raw-material and vendor risks.

Proprietary AAV platform and CNS delivery expertise (PASG on NASDAQ) accelerate multi‑indication development and reduce clinical translation risk.

Patents, trade secrets, and 2024 freedom‑to‑operate analyses protect modality rights and guide indication selection.

GMP suites, validated QC, preclinical/clinical/natural‑history datasets and digital biomarkers underpin filings and commercialization.

Orphan-focused strategy leverages US orphan drug exclusivity of 7 years and expedited pathways (priority review target 6 months) to shorten timelines. Biomarker-rich, often sub-50 patient trials accelerate signal detection and de‑risk go/no-go decisions. Patient-centric endpoints capture functional benefit valued by regulators and payers, enabling faster availability for underserved populations.

One-time, disease‑modifying AAV CNS therapies offer durable benefit vs lifelong care (Zolgensma precedent US$2.125M) and can cut lifetime rare‑disease costs often >US$1M. Engineered AAVs enable neuron/glia targeting for high‑unmet CNS markets (Parkinson’s ≈10M; dementia ≈55M). Orphan exclusivity (7 years) + expedited pathways and 3–5yr RWE (2024) de‑risk commercialization.

Case managers coordinate testing, insurance authorization and logistics for clinical and commercial access, streamlining patient journeys. Multilingual resources reach global rare-disease populations — over 300 million people worldwide. Structured follow-up programs support adherence to monitoring and treatment schedules. Continuous feedback loops capture outcomes and patient experience to refine services.

Quarterly KOL forums and MSLs drive clinician trust and guideline adoption, aiding PASG (NASDAQ) 2024 launch plans. Case managers and COEs streamline access; >90% site readiness in partnered centers supports consistent delivery. Early payer talks enable outcomes-based contracts to mitigate reimbursement risk.

Patient advocacy networks raise awareness and drive trial participation by mobilizing communities; WHO estimates 300 million people live with rare diseases globally (2024). Educational toolkits demystify gene therapy basics for patients and HCPs. Registry links facilitate screening and referrals. Two-way communication captures unmet needs and informs protocol design.

Therapies via specialized hospitals with centralized hubs for evaluation and follow-up; site enablement accelerates readiness. Outreach uses journals, ASGCT/AAN, registries and patient groups to drive referrals; telehealth ~10% of visits (2024). 2024 alliances/co-promote expanded regional reach, lowering launch capital.

Neurologists and genetic specialists are primary prescribers and referral sources for CNS gene therapies, guiding patient selection and center referrals; rare diseases affect about 300 million people worldwide (WHO). They demand robust evidence, standardized protocols and long‑term safety data — critical given landmark approvals such as Luxturna (2017) and Zolgensma (2019). Their endorsement drives center adoption and standard‑of‑care evolution. Engagement focuses on KOL networks, investigator education and consensus guideline development.

Patients with monogenic CNS disorders (~300M people globally; ~30M US rare disease patients in 2024; ~50% pediatric) are high-need, high-willingness targets. Caregivers (20–25 hrs/week) drive decisions and need care/navigation support. Neurologists/geneticists and HTA/payers demand robust long-term evidence and outcomes-linked pricing; 2024 gene therapy market ≈ $8.3B.

Clinical trials & operations drive major costs for Passage Bio: site fees, CRO services, imaging and lab analyses commonly consume 40–60% of trial budgets in 2024, with specialized imaging and assays especially costly. Patient support and logistics for rare populations can exceed $50,000 per patient in 2024 due to travel, housing and concierge services. Data management, monitoring for regulatory compliance, and safety oversight including DSMB activities add substantial recurring costs and vendor fees.

Platform R&D drives high fixed costs (platform spend >$100M/year). GMP AAV batches run ~ $2M each (industry median 2023); validation adds 10–20% overhead. Clinical ops consume 40–60% of trial budgets (2024); patient support often > $50,000/patient (2024). Regulatory filing fees (FDA BLA FY2024) ≈ $3.24M.

Passage Bio can out-license vectors, promoters, or delivery methods to peers, capturing upfront fees and milestone payments while the global gene therapy market was estimated at about $7.8 billion in 2024. Royalties on partnered products create recurring revenue streams. Field-limited rights protect core programs while cross-licenses unlock new indications and collaborative R&D.

Passage Bio’s revenue model centers on future AAV product sales (benchmarked by Zolgensma ≈ $2.1M, Luxturna ≈ $425k) plus outcomes‑linked commercial arrangements. Partner upfronts commonly range $5–100M with total deal values often reaching high hundreds of millions; royalties and out‑licenses tap a gene therapy market ~ $7.8B in 2024. Grants, PRVs (saleable for up to several hundred million) and milestone payments provide non‑dilutive cash and optionality.